Related Experiment Videos

Suicide gene therapy for plasma cell tumors

M S Dilber1, M R Abedi, B Björkstrand

  • 1Department of Medicine, Karolinska Institute at Huddinge Hospital, Sweden.

Blood
|September 15, 1996
PubMed

Insights

Suicide gene therapy using herpes simplex thymidine kinase (HSVtk) and ganciclovir (GCV) eradicated myeloma tumors in mice. A surprising distant bystander effect was observed, impacting non-treated tumors.

Area of Science:

  • Oncology
  • Gene Therapy
  • Cancer Research

Background:

  • Plasma cell tumors, like multiple myeloma, are challenging to treat.
  • Suicide gene therapy offers a novel therapeutic strategy.
  • The herpes simplex thymidine kinase (HSVtk)/ganciclovir (GCV) system is a well-studied suicide gene therapy approach.

Purpose of the Study:

  • To evaluate the efficacy of HSVtk/GCV suicide gene therapy against human myeloma cell lines in severe combined immunodeficient (SCID) mice.
  • To investigate the in vitro and in vivo bystander effects of this gene therapy approach.
  • To explore the potential for a "distant bystander" effect.

Main Methods:

  • Human myeloma cell lines were transduced with the HSVtk gene.
  • In vitro studies assessed ganciclovir-induced cytotoxicity.
  • SCID mice were injected with either transduced cells, mixtures of transduced and non-transduced cells, or cells at different locations to assess in vivo and distant bystander effects.
  • Tumor growth, apoptosis, and mitotic frequency were analyzed.

Main Results:

  • Ganciclovir effectively eradicated HSVtk-transduced myeloma cells in vitro.
  • Subcutaneous injection of HSVtk-transduced cells in SCID mice led to tumor eradication upon ganciclovir administration.
  • A significant in vivo bystander effect was observed when mixtures of transduced and non-transduced cells were present.
  • A notable "distant bystander" effect was documented, with significant tumor reduction and increased apoptosis in non-transduced tumors located separately from the treated site.

Conclusions:

  • HSVtk/GCV suicide gene therapy is effective against human myeloma xenografts in SCID mice.
  • The therapy demonstrates both direct cytotoxic and significant bystander effects, including a distant bystander effect.
  • These findings support the potential of suicide gene therapy for treating plasma cell tumors, warranting further investigation.

Related Concept Videos